Background The prevalence of hepatitis E virus (HEV) genotype 3 infections in the English population (including blood donors) is unknown, but is probably widespread, and the virus has been detected in pooled plasma products. HEV-infected donors have been retrospectively identifi ed through investigation of reported cases of possible transfusion-transmitted hepatitis E. The frequency of HEV transmission by transfusion and its outcome remains unknown. We report the prevalence of HEV RNA in blood donations, the transmission of the virus through a range of blood components, and describe the resulting morbidity in the recipients.
Introduction
Hepatitis E was fi rst recognised as a clinical disease in 1978 as an outbreak of epidemic non-A, non-B hepatitis in Kashmir. 1 In 1990, faecal extracts from cases in a Russian military camp were shown to be infectious orally in people and domestic pigs, 2, 3 with the infective agent hepatitis E virus (HEV) being partly sequenced the same year. 4 There are four HEV genotypes-1 and 2 (human viruses), and 3 and 4 (animal viruses) that infect human beings zoonotically. The results of a recent population-based seroprevalence study in England and Wales suggested that the prevalence of infection is more common than would be expected from an imported infection and that 25% of adults in the sixth and seventh decades of life are seropositive. 5 In the UK, the numbers of cases of hepatitis E have increased every year since 2010 6 and this increase is associated with the emergence of a viral phylotype not previously seen. HEV is now the most common infective cause of acute enterically transmitted viral hepatitis and is detected in people who have not travelled outside the UK. 7 The association between hepatitis E and con sumption of processed pork products makes hepatitis E a likely zoonosis in the UK 8 and other countries where viral sequencing has implicated food containing animal products from pigs, 9 boar, 10 and deer. 11 The fi rst transmission in the UK of HEV from a blood component reported in 2006 12 was identifi ed retrospectively in the recipients of blood components from a donor diagnosed with hepatitis E 24 days after donation. Post-transfusion hepatitis E seems unusual and since the fi rst report eight post-transfusion HEV enquiries (two in 2013, fi ve in 2012, and one in 2011) have been notifi ed to the National Health Service Blood and Transplant (NHSBT). Only the two most recent cases were confi rmed to be linked to components from an infected donor. HEV RNA in UK plasma pools 13, 14 and serological evidence of recent HEV infection in donors 15 have also been documented, indicating a turnover of HEV in donors, but neither fi nding provides a measure of the prevalence of viraemia. Intercurrent immuno -suppression, common in component recipients, can delay viral clearance and lead to viral persistence in patients with solid organ transplant 16 and HIV infection. 17, 18 These fi ndings have raised the question of whether the hazard from HEV infection in donors ought to be defi ned. We report here the prevalence of HEV RNA in blood donors, the transmission of HEV by a range of components, and we describe the resulting morbidity in recipients.
Methods
This study and related protocols were presented to the London Bridge Research Ethics Committee (reference 12/LO/0987) and approval was received in September, 2012. An overarching data monitoring committee maintained an independent continuous review of the progress of the study. A study steering group, reporting to the data monitoring committee, reviewed all aspects of the study on a weekly basis. Identifi cation and clinical follow-up of exposed recipients were coordinated by the NHSBT in accordance with existing protocols for the discharge of the duty of care to recipients of components carrying previously unidentifi ed risks.
From Oct 8, 2012 of England from consenting donors were dispatched from NHSBT Filton, Bristol, to NHSBT Colindale, London, UK, where minipools of 24 donations, or fewer if a full 24 set was not available at the time of pooling, were assembled and extracted on the QiaSymphony (Qiagen, Crawley, UK; virus-specifi c cell-free protocol). At any point in time, staff and equipment limitations determined whether all sequential donations were taken for pooling or discarded. 9382 minipools were screened for HEV RNA during the study. HEV RNA was detected with an internally controlled RT-PCR 19 (detection limit 22 IU/mL). Briefl y, extracted nucleic acid in 10 μL was reverse transcribed in 25 μL with Quantitect Probe rt-pcr (Qiagen, Crawley, UK) and then amplifi ed through 45 cycles. Sample reactivity was ascribed an RNA value in IU/mL by comparison with a standard curve of serial log 10 dilutions in normal human plasma of a high titre sample of known potency in WHO international units. Reactive pools were resolved to individual donations that were then subjected to HEV RNA detection, quantifi cation, phylogeny, and serology. Plasma RNA was amplifi ed, sequenced, and subjected to phylogenetic analysis across part of the open reading frame 2 as previously described. Unused blood components remaining in the NHSBT inventory were discarded and those already issued were recalled. A standard look back (ie, check) was initiated for all transfused components. The involved hospital trans fusion team was asked to identify the recipient and the clinical team providing patient care. The clinical team (or family doctor if the recipient had been discharged) was advised of the possible exposure to HEV and sent information about HEV and a suggested recipient follow-up plan.
Through the attending clinician, clinical information on all of the recipients was sought. Where possible, blood samples were collected during the follow-up. Negative serology at 16 weeks post-transfusion and an absence of HEV RNA at any stage indicated the lack of transmission. The detection of plasma RNA at any stage or seroconversion or serological markers of recent infection indicated transmission. Any recipient with viraemia was monitored until HEV RNA clearance and the development of both IgG and IgM.
Role of the funding source
This study was jointly funded by Public Health England and the NHSBT. Pooling was done on NHSBT premises. Serology, molecular testing, and phylogenetic analysis were done on Public Health England premises. Donor records, including consent for testing, enrolment, and clinical data were maintained by the NHSBT. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
9382 minipools, comprising 225 000 individual donations, were screened and 79 donations containing HEV RNA were identifi ed, giving a prevalence of about one in 2848 donations (0·04%). 56 (71%) donors were sero negative (negative for anti-HEV IgM and anti-HEV IgG). The median viral load was 3900 IU/mL (range 50 to 2·37 × 10⁶) and was 0·5 log 10 higher in index donations that were antibody negative. 54 (68%) of 79 donor samples could be genotyped and all had a genotype 3 virus (fi gure 1).
129 components were manufactured from 79 donations (table 1) . Red cells comprised the largest number (71 [55%]) followed by platelets (39 [30%]), but, because of discard or recall, only 62 (48%) components were given as transfusions to 60 recipients: one patient received two aliquots of an apheresis platelet donation, and another received two separate HEV-containing components (table 1) . Platelets were the most commonly transfused virus-containing blood component (table 1) .
Of the 60 patients given blood components from HEV-infected donors, one declined investigation. 16 patients were not available for follow-up: nine died soon after transfusion and before follow-up, fi ve were terminally ill or incapacitated and therefore the initiation of HEV monitoring was thought to be inappropriate, and Data are number or number (%). Table 2 : Association between transfused blood components and transmission of hepatitis E virus in 43 of 60 exposed patients in whom follow-up was possible two had returned to their country of origin. In no case did the clinical team judge that HEV had contributed to any illness or to death. Therefore, 43 patients were followed up (table 2) . Six patients (1-3, 6, 7, and 10) had serological markers of the recent development of antibody (seroconversion) when fi rst tested at a median of 6 weeks (range 3-14 weeks) after transfusion (table 3) . High concentrations of anti-HEV IgG (sample/cutoff [S/CO] >20) were detected in all samples, IgM was detected in one sample (S/CO 1·2), and borderline IgM (S/CO 0·7-0·9) was detected in three samples. A further 12 recipients were viraemic at one or more timepoints in the post-transfusion period (table 3) . Taking both groups together, the overall transmission rate was 42% (18 of 43 exposed patients), supported by the fi nding of sequences in each of the 12 viraemic recipients that were identical to sequences from the involved donors (fi gure 1). 25 recipients were judged to not have been infected, 16 of whom had no serological evidence of HEV infection at 16 weeks after transfusion and nine who were both seronegative and non-viraemic at 8 weeks or longer after transfusion.
The components associated with transmission of HEV to recipients are shown in transmission. The antibody levels were much lower in the four donations that resulted in transmission than in the 13 that did not (fi gure 2A). The HEV viral load was about 1·5 log 10 higher in the donations that transmitted than in those that did not (fi gure 2B). Follow-up of the infected recipients showed a varied response to infection, refl ecting their overall clinical state and inferred degree of immunosuppression. The median times for seroconversion and duration of infection increased in patients as the degree of immunosuppression increased (table 3) . Eight patients (1-8) were deemed to be immunocompetent or only mildly immunosuppressed (table 3) . Five patients cleared their infection without having detectable viraemia, the other three recipients cleared their RNA in a median of 10 weeks (table 3) . Six patients (9-14) with varying degrees of moderate immunosuppression had a longer median time of 11 weeks to seroconversion and a median duration of viraemia of 18 weeks (table 3) . Four patients (15-18) were judged to be heavily immunosuppressed. In these patients, seroconversion was either very delayed (week 38 for patient 15 and week 37 for patient 18) or was not detected.
In three viraemic recipients, one moderately (patient 12) and two severely immunosuppressed (patients 16 and 18), an elective decision was made to induce viral clearance. In patient 12, steroid dose reduction and withdrawal of additional immunosuppressive drugs 9 weeks after transfusion led to seroconversion and viral clearance over 3 weeks. In patient 18, changes in immunosuppressive therapy coincided with the onset of seroconversion at 37 weeks and subsequent viral clearance from both stool and plasma. In patient 16, 2 weeks of ribavirin was given between cycles of chemotherapy at 12 weeks after transfusion and led to a 1000 times reduction in HEV RNA concentrations but not to clearance. Further ribavirin treatment starting at 19 weeks after transfusion led to viral clearance in the absence of a detectable antibody response.
Clinical hepatitis was reported in only one recipient (patient 4), whose indication for transfusion was a cardiac surgical procedure (table 3). 5 weeks after transfusion, the patient consulted with the family doctor and was confi rmed to have hepatitis, associated with HEV seroconversion. Four other recipients (patients 8, 11, 12, and 14) had asymptomatic transaminitis coincident with seroconversion, which was triggered in patient 12 by a change in therapy. Transaminitis was marked in patient 14 in whom plasma alkaline phosphatase was also elevated for 1 week before the fi rst development of anti-HEV antibodies. No infected patient was reported to have neurological disease.
Discussion
The prevalence of blood donations containing HEV RNA was higher than anticipated in the planning of the project. When projected across the country, and allowances are made for the duration of a detectable viraemia for 8 weeks, a prevalence of one in 2848 indicates that about 80 000-100 000 acute HEV infections are likely to have occurred in England during the year of the study. This is close to the modelled estimate 20 and shows a truly sizeable zoonosis, including both group 1 and group 2 viruses of genotype 3 HEV, 7 which was also transmitted to the donors identifi ed in this study (fi gure 1). Similar prevalences of viraemia have been reported in Sweden and Germany, [21] [22] [23] suggesting that this zoonosis is also widespread across the European continent, further supported by a recently reported case of post-transfusion HEV in France (panel). 24 The inevitable delay between donation and the identifi cation of a viraemic donor meant that when recall of components was started, a high proportion of the short shelf-life components had already been transfused and most of the recalled units were inevitably of the longer shelf-life red cell and frozen components. This might have altered the profi le of recipients towards those who were immunosuppressed and requiring platelet support.
Two linked variables in the donor plasma that were associated with transmission were the anti-HEV status of the donation and the level of virus in the plasma (fi gure 2A, 2B). Overall, donations containing antibody were less likely to transmit and, when they did, there was a trend for lower levels of anti-HEV to be associated with transmission. Donations associated with transmission had signifi cantly higher levels of plasma RNA (p<0·0001) than did those not associated with transmission, but overall viral RNA levels were ten times lower in viraemic donors than in the plasma of patients presenting with acute clinical hepatitis E (median 6·2 × 10⁴ IU/ml, range 20 to 4·2 × 10⁷; unpublished data). In this study it was not possible to ascertain the serological status of the recipient before transfusion because of the unavailability of samples.
The numbers of components in each category were insuffi cient for a robust attribution of transmissibility, though there is clearly a trend for those components that contain larger plasma volumes, principally fresh frozen plasma and platelet components, to transmit more readily. Despite this, in some instances apparently susceptible individuals who were challenged with components prepared from donors with high-level HEV viraemia did not become infected, raising the question of whether some people are innately resistant to infection or whether coincidental administration of antibodycontaining components from other donors might also have mitigated the risk of infection. Table 3 shows that the immunological integrity of the host materially alters the time course of the posttransfusion infection. Increasing immunosuppression prolongs viraemia and delays seroconversion. Although eight of 12 viraemic recipients underwent seroconversion, coinciding in some with a biochemical transaminitis, seroconversion does not necessarily bring about clearance and can still be followed by longterm viraemia (patients 13 and 15). At the other end of this range, four heavily immuno suppressed patients either did not produce anti-HEV or had very delayed seroconversion and exhibited prolonged viraemia as described previously in recipients of solid organ transplants. 16 What is of concern in this small series is that ten patients infected through transfused components seemed likely to be at the beginning of long-term persistence. Two patients (8 and 14) cleared viraemia spontaneously late after infection, four (9, 11, 15, and 17) remained viraemic at time of their deaths, and four (12, 13, 16, and 18) were at risk of chronic liver disease and requiring continued monitoring and possible inter vention. In three cases, the decision to attempt viral clearance was made. Indirect antiviral intervention with electively reduced immunosuppression led to seroconversion and viral clearance in two recipients (10 and 18) . Direct antiviral intervention with ribavirin led to resolution of the infection without seroconversion in patient 16. The fourth patient (13) remains the only persistently infected recipient a year after transfusion.
Our fi ndings confi rm the potential danger of transfusion-transmitted HEV in the transplant and haemoncology settings but also the susceptibility of this persistent infection to immune clearance. Persistent infection might be more of a hazard for recipients of solid organ transplant in whom the immunosuppression is unremitting than for recipients of stem cell transplantation in which immune recovery might be expected. Based on the fi nding of little acute morbidity, there is no indication to alter previously optimised treatment pathways for patients who have been exposed or infected with HEV. Two-thirds of patients are likely to clear infection spontaneously, and when long-term persistence develops intervention can be undertaken electively. 25 Immune recovery is the desired outcome in many haematological situations and this alone might well bring about viral clearance that might also be associated, like seroconversion, with an illness during viral clearance. 26 Since HEV infection transmits through transfusion and the incidence of acute infection in donors from the southeast of England is high, about 1200 HEV-containing components are likely to be released for transfusion purposes each year in England. Most infections will not be identifi able through any acute illness in the immediate post-transfusion period but might present much later at the time of immune reconstitution or as a manifestation of long-term chronic liver disease, especially in solid organ transplants when an association with transfusion might not be made. One way of mitigating unfavourable outcomes would be to introduce routine yearly screening for persistent HEV infection in all transplant patients with an option to treat those who are chronically infected independent of the route of infection.
Setting aside this option, what would be a proportionate response to this zoonosis? Is it possible to deal with the source of infection that is likely to be foods containing pork, 8 perhaps advising patients at risk to modify their diet as is done for listeria? A societal change reverting to the old principle of extended cooking of pork would not fi t with the tendency to consume it lightly cooked now that trichinosis is no longer a perceived hazard. 27 Addressing animal husbandry and determining how to 
Systematic review
We searched MedLine for articles published in the 7 years up to December, 2013, on the topic of HEV and blood safety. We used a range of keywords including "hepatitis E", "HEV", "blood safety", "transmission", "blood donors", and "recipients". In the past 10 years hepatitis E virus (HEV) has been increasingly recognised as a zoonotic infection in highincome countries where it was previously thought to be an imported infection. Current infection in blood donors and a small number of post-transfusion cases from some countries indicate a potential for transmission by transfusion. No systematic analysis of transmission rates and clinical eff ect of transfusion-transmitted HEV exists in published literature.
Interpretation
We have defi ned the prevalence of viraemic donors and transmission to recipients. Spontaneous clearance without clinical disease was common, despite delayed seroconversion, and resulting acute illness was rare. Our data are from the fi rst reported systematic study of HEV transmission from donors infected by an extensive but largely non-apparent zoonosis in England. On a clinical basis alone, the resulting minimal burden of disease does not signal a pressing need for donation screening at this time.
control HEV in pig herds remains a possibility, although an easily transmissible enteric agent like HEV 28 will be more diffi cult to control than trichinella. Alternatively, screening of blood donations, at substantial cost, on the basis of reducing the risk of long-term infection, would remove the bulk of the transfusion hazard but still allow the dietary risk to transplant patients; this issue was addressed in Toulouse, France, by the removal of the fi gatelu liver sausage from the hospital diet. 9 Nevertheless, every donor exposure in England and Wales will increase the likelihood of recipient infection by one in 3000, and if a recipient in 1 year of treatment were to be exposed to components from 20 donors the accumulated yearly risk from transfusion would be one in 150 compared with a dietary risk of one in 500-1000, modelled on the yearly seroconversion rate of 0·1-0·2%. Our experience in this study, however, indicates that the burden of harm engendered by HEV acquisition through transfusion is very slight and from a clinical perspective alone there seems no pressing need to move rapidly with the introduction of donation screening. The broader issues of HEV and blood safety, including the need for donation screening, 29 will be addressed in the UK later this summer after the recent commissioning of a short-life expert committee of the UK Departments of Health Advisory Committee on the Safety of Blood, Tissues and Organs to consider these matters within the context of a fi nancially constrained health service.
The magnitude of the current zoonosis in Europe is shown by both more cases of hepatitis E being reported for England in 2012 than in 2011, 7 and an increase in prevalence of HEV antibody in young Dutch blood donors (Zaaijer H, Sanquin Blood Supply Foundation, personal communication). It should be borne in mind that HEV disease in England and Wales shows considerable temporal variation, and though the magnitude of the risk now possibly justifi es intervention 30 it is unlikely that the high frequency of acute infection will be maintained indefi nitely; this provides another complication in the decision of an appropriate response to this interesting and rather unexpected transfusionassociated infection in the UK.
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